Standout Papers

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis 2017 2026 2020 2023 382
  1. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis (2017)
    Kim Papp, Andrew Blauvelt et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Dendritic cell maturation in cancer
2025 Standout
Atopic dermatitis
2025 Standout
3 intermediate papers

Works of Michael Bukhalo being referenced

Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)
2022
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
2017 Standout

Author Peers

Author Last Decade Papers Cites
Michael Bukhalo 507 357 40 108 17 657
Robert E. Kalb 530 327 46 39 17 665
Darío Kivelevitch 464 237 26 88 21 593
S. Li 571 331 59 134 22 658
A.L.A. Kuijpers 470 236 75 76 23 697
P.P.M. van Lümig 486 292 105 79 17 589
Stewart Adams 384 293 19 45 20 634
Cynthia Madden 552 344 27 100 20 794
Elisa Camela 612 472 67 144 41 753
Warren W. Epinette 257 213 29 46 17 657
Nicole Seminara 613 267 14 56 11 811

All Works

Loading papers...

Rankless by CCL
2026